Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Strategic Investment Advisors MI

Strategic Investment Advisors MI boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 385 shares of the biopharmaceutical company’s stock after acquiring an additional 31 shares during the quarter. Strategic Investment Advisors MI’s holdings in Regeneron Pharmaceuticals were worth $275,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in REGN. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $37,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $49,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Citigroup dropped their price objective on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a report on Tuesday, January 14th. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Evercore ISI cut their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,006.71.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $684.71 on Tuesday. The firm’s 50-day moving average is $727.19 and its two-hundred day moving average is $936.01. Regeneron Pharmaceuticals, Inc. has a 12 month low of $666.25 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market capitalization of $75.24 billion, a PE ratio of 16.94, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.